Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L De Haan

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Psychological Medicine|March 29, 2012
Age at onset of non-affective psychosis in relation to cannabis use, other drug use and genderN Dekker, J Meijer, M Koeter, et al.
Neuroimage. Clinical|October 5, 2023
fMRI connectivity as a biomarker of antipsychotic treatment response: A systematic reviewL S Dominicus, L van Rijn, J van der A, et al.
Psychological Medicine|May 20, 2016
Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosisG Bakker, M W A Caan, R S Schluter, et al.
Acta Psychiatrica Scandinavica|July 11, 2012
The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosisD H Nieman, E Velthorst, H E Becker, et al.
Tijdschrift Voor Psychiatrie|June 16, 2015
[Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument]D Wiersma, E Visser, M Bähler, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
Psychological Medicine|March 7, 2024
Associations between disturbed sleep and attenuated psychotic experiences in people at clinical high risk for psychosisM J C Formica, M Fuller-Tyszkiewicz, U Reininghaus, et al.
Tijdschrift Voor Psychiatrie|March 6, 2010
[Routine Outcome Monitoring for patients with severe mental illness: a consensus document]C L Mulder, M van der Gaag, R Bruggeman, et al.
Acta Psychiatrica Scandinavica|September 3, 2011
Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosisS Dragt, D H Nieman, F Schultze-Lutter, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Psychological Medicine|March 29, 2012
Age at onset of non-affective psychosis in relation to cannabis use, other drug use and genderN Dekker, J Meijer, M Koeter, et al.
Neuroimage. Clinical|October 5, 2023
fMRI connectivity as a biomarker of antipsychotic treatment response: A systematic reviewL S Dominicus, L van Rijn, J van der A, et al.
Psychological Medicine|May 20, 2016
Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosisG Bakker, M W A Caan, R S Schluter, et al.
Acta Psychiatrica Scandinavica|July 11, 2012
The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosisD H Nieman, E Velthorst, H E Becker, et al.
Tijdschrift Voor Psychiatrie|June 16, 2015
[Functional remission of people with serious mental illness (SMI): psychometric properties of a new ROM-instrument]D Wiersma, E Visser, M Bähler, et al.
Schizophrenia Research|October 23, 2017
The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quoM J McHugh, P D McGorry, H P Yuen, et al.
Psychological Medicine|March 7, 2024
Associations between disturbed sleep and attenuated psychotic experiences in people at clinical high risk for psychosisM J C Formica, M Fuller-Tyszkiewicz, U Reininghaus, et al.
Tijdschrift Voor Psychiatrie|March 6, 2010
[Routine Outcome Monitoring for patients with severe mental illness: a consensus document]C L Mulder, M van der Gaag, R Bruggeman, et al.
Acta Psychiatrica Scandinavica|September 3, 2011
Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosisS Dragt, D H Nieman, F Schultze-Lutter, et al.
NPJ Schizophrenia|June 27, 2018
NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders-medium-term follow-up and clinical courseB Nelson, G P Amminger, H P Yuen, et al.
Pageof 13